Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 2 (1)
P 3 (1)

Trial Status

Enrolling By Invitation2
Unknown2

Clinical Trials (4)

Showing 4 of 4 trials
NCT07450040Enrolling By Invitation

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

NCT07449949Enrolling By Invitation

A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma

NCT05267366Phase 2Unknown

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

NCT02629718Phase 3Unknown

Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer

Showing all 4 trials

Research Network

Activity Timeline